An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in
patients with active moderate to severe rheumatoid arthritis. Participants will receive a
subcutaneous dose of tocilizumab 162 mg once weekly. The anticipated time on study treatment
is 24 weeks.